🔴 Structure Therapeutics is trading 4.3% down today despite positive September 8 clinical data

Structure Therapeutics is trading 4.3% down at $45.28 after a broader risk-off session in U.S. equities.

• Geopolitical tensions, higher oil prices, tariff escalation, and shifting Federal Reserve expectations weighed on sentiment.
• The company reported positive September 8 clinical data for ACCG-2671 and aleniglipron, including up to 16.2% weight loss; the announcement does not explain the decline.
• The move was significantly weaker than the Nasdaq’s 0.35% decline, suggesting company-specific selling or profit-taking, though no clear negative catalyst was identified.